v3.19.3.a.u2

Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 34 Months Ended | 53 Months Ended |
--- | --- | --- | --- | --- | --- | ---
May 31, 2018 USD ($) | Apr. 30, 2018 USD ($) | Jun. 30, 2016 USD ($) | Jan. 31, 2016 USD ($) | Jan. 31, 2015 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 | May 31, 2019 USD ($) candidate | Jan. 01, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 60,209,000 |  |  |  |  |
Collaboration revenue |  |  |  |  |  | $ 14,055,000 | $ 17,046,000 | $ 13,083,000 | $ 16,025,000 | $ 35,421,000 | $ 41,757,000 | $ 28,851,000 | $ 29,039,000 | 60,209,000 | $ 135,068,000 | $ 205,825,000 |  |  |
Transaction price |  |  |  |  |  | 249,500,000 |  |  |  |  |  |  |  | 249,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  | 199,528,000 |  |  |  | 240,924,000 |  |  |  | 199,528,000 | 240,924,000 |  |  |  |
Series H Redeemable Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate net proceeds from the offering | $ 112,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium recorded to deferred revenue | $ 13,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  | 42,803,000 |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 42,803,000 | 76,519,000 | 146,953,000 |  |  |
Merck Agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years | 3 years |
Number of product candidates | candidate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |
Increase (decrease) in deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |
Upfront cash payments |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000,000.0 |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24,600,000 | 22,900,000 |  |  |
Proceeds from equity investment |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years | 4 years |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 65,000,000
Increase to the transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  | (5,300,000) |  |  |  |  |
Deferred revenue |  |  |  |  |  | 0 |  |  |  |  |  |  |  | 0 |  |  |  |  |
Separate Agreements With Merck | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  | (4,800,000) |  |  |  |  |
PCV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payments |  |  | $ 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PCV Agreement | Series H Redeemable Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate net proceeds from the offering |  | $ 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium recorded to deferred revenue |  | 13,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PCV Agreement | PCV products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  | $ 243,000,000 |  |  |  | 243,000,000 |  |  |  | 243,000,000 |  |  |  | 243,000,000 | 243,000,000 |  |  |  |
PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 213,000,000
Increase to the transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Deferred revenue |  |  |  |  |  | 83,800,000 |  |  |  | $ 111,300,000 |  |  |  | 83,800,000 | 111,300,000 |  |  |  | 125,200,000
PCVSAV Agreement | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  | 41,400,000 | $ 41,500,000 | $ 40,000,000 |  |  |
Milestone Payments | Merck Agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000
Upfront Payment | Merck Agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000
Upfront Payment | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000,000
Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,000,000
Upfront Payment, Research And Development | Merck Agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000
Upfront Payment, Funding From 2016 Amendment | Merck Agreement 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000
PCV Performance Obligation | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  | 206,300,000 |  |  |  |  |  |  |  | 206,300,000 |  |  |  |  |
KRAS Performance Obligation | PCVSAV Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  | $ 6,700,000 |  |  |  |  |  |  |  | $ 6,700,000 |  |  |  |  |

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Maximum Amount + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Performance Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Research Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share. + References No definition available. + Details
Name: | us-gaap_RedemptionPremium
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentFundingFrom2016AmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |